Aldeyra Therapeutics (ALDX) Total Current Liabilities (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Total Current Liabilities for 14 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 67.31% year-over-year to $9.7 million; the trailing twelve-month figure through Jun 2026 stood at $9.7 million (down 67.31% YoY), and the FY2025 full-year result was $27.8 million, up 49.5% from the prior year.
• Total Current Liabilities eased to $9.7 million in Q2 2026 per ALDX's latest filing, from $24.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $29.5 million in Q2 2025 and bottomed at $9.7 million in Q2 2026.
• Historically, Total Current Liabilities has averaged $20.4 million across 5 years, with a median of $20.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 119.23% in 2022, then plunged 67.31% in 2026.
• Over 5 years, Total Current Liabilities stood at $15.4 million in 2022, then soared by 44.92% to $22.3 million in 2023, then slipped by 16.43% to $18.6 million in 2024, then surged by 49.5% to $27.8 million in 2025, then slumped by 65.28% to $9.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.7 million, $24.3 million, and $27.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.